Atlas Trials

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Clinical trial NCT06107413 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06107413
Sponsor
AbbVie
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Metastatic Colorectal Cancer
Start date
2023-11-12
Primary completion
2026-12-01
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.